Homepage
Author:
Chamberlain Communications Group LLC / on behalf of Mitsubishi Tanabe Pharma America
Posted Date:
April 1, 2026
Tanabe Pharma America Announces Finalization of RADICAVA (edaravone) Transfer to Shionogi
Chamberlain Communications Group LLC / on behalf of Mitsubishi Tanabe Pharma America
April 1, 2026
/C O R R E C T I O N — American Academy of Pediatrics/
Chamberlain Communications Group LLC / on behalf of Mitsubishi Tanabe Pharma America
March 16, 2026
Federal Judge Blocks Immunization Schedule Changes, Stays ACIP Member Appointments
Chamberlain Communications Group LLC / on behalf of Mitsubishi Tanabe Pharma America
March 16, 2026
Tanabe Pharma America to Highlight Research in ALS at 2026 MDA Clinical and Scientific Conference
Chamberlain Communications Group LLC / on behalf of Mitsubishi Tanabe Pharma America
March 5, 2026
